Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials
By
- AMS
posted
Oct 21, 2020 10:07 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials
- AMS
Added Jan 04, 2020
Blog Entry
Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey
- AMS
Added Nov 02, 2020
Blog Entry
A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
- AMS
Added Apr 21, 2020
Blog Entry
Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis
- AMS
Added Jun 08, 2020
Blog Entry
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
- AMS
Added Apr 30, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic